

**Supplementary Table 1.** Baseline demographic and clinical characteristics of axSpA patients (n=78) included in the analysis and patients that were excluded for missing data (n = 52).

Parameter	Study cohort	Patients with missing data	p
Female sex	25 (32.1%)	19 (36.5%)	0.666
Age (years)	36.87±10.42	35.75±10.63	0.554
BMI (kg/m <sup>2</sup> )	25.55±4.42	24.15±3.82	0.063
HLA B27 positive	72 (92.3%)	44 (84.6%)	0.578
Symptom duration (years)	11.96±10.43	9.66±8.08	0.161
BASDAI	5.48±1.36	5.65±1.43	0.511
ASDAS	3.46±0.79	3.38±0.79	0.607
CRP (mg/l)	13.47±15.37	12.38±19.95	0.742
Elevated CRP (>5 mg/l)	46 (61.3%)	28 (54.9%)	1
NSAID intake	63 (80.8%)	39 (75%)	0.68
bDMARD (TNFi / IL-17i)	76 (97.4%)/2 (2.6%)	48 (92.31%)/0 (0%)	0.002*
Arthritis, ever	23 (29.5%)	23 (44.2%)	0.819
Enthesitis, ever	36 (46.2%)	27 (51.9%)	0.543
Dactylitis, ever	6 (7.7%)	1 (1.9%)	0.877
Uveitis, ever	19 (24.4%)	10 (19.2%)	0.484
Inflammatory bowel disease, ever	5 (6.4%)	4 (7.7%)	0.182
Psoriasis, ever	12 (15.4%)	7 (13.5%)	0.572

ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, bDMARD biological disease-modifying anti-rheumatic drug, BMI Body Mass Index, CRP C-reactive protein, HLA Human leukocyte antigen, IL Interleukin, NSAID non-steroidal anti-inflammatory drugs, PD PainDETECT, TNF Tumor Necrosis Factor, WPI Widespread Pain Index

\* P value was calculated for differences in all bDMARDs use.

P values were calculated with the t-test for continuous variables and Chi-squared test for categorical variables. Continuous variables are expressed as mean ± standard deviation and categorical variables as n (%).